Nafeez Ahmed explores the troubling implications and assumptions of the Governments AI-driven gene programme.
In Part 1 of this investigation, I looked at how the convergence of an AI Superstate and corporate interests with health data lies at the heart of a new frontier for profit and surveillance. But the Governments response during the COVID-19 pandemic has revealed something even more profoundly disturbing: a fascination with genomics which moves from a merely descriptive tool to something so prescriptive it verges on eugenics.
The NHSX app is simply one project with a questionable design which appears to result from the Governments much wider project to remake the NHS.
At the core of the new NHSX AI drive is the goal of predictive, preventive, personalised and participatory medicine, according to an NHSX document published in October 2019. Pivotal to this AI-driven transformation is genetics:
Key to unlocking the benefits of precision medicine with AI is the use of genomic data generated by genome sequencing. Machine learning is already being used to automate genome quality control. AI has improved the ability to process genomes rapidly and to high standards and can also now help improve genome interpretation.
The NHS Genomic Medicine Service is starting with a focus on cancer, rare and inherited diseases,but its broader goal is far more comprehensive. Initially, the hope is that genomics will expand to cover other areas, such as pharmacogenomics, which looks at how an individuals genes influence a particular biological process that mediates the effects of a medicine, according to The Pharmaceutical Journal.
But the end-goal is to convert the NHS into a health service oriented fundamentally around the role of genetics in disease. The aspiration is that from 2020, and by 2025, genomic medicine will be an embedded part of routine care to enable better prediction and prevention of disease and fewer adverse drug reactions. The GMS aims to complete five million genomic analyses and five million early disease cohorts over the next five years.
By 2025, genomic technologies will be embedded through multiple clinical pathways and included as a fundamental part of clinical training. As a result, it is hoped that there will be a new taxonomy of medicine based on the underlying drivers of disease.
But, this entire premise is deeply questionable. There is little evidence that the underlying drivers of disease are primarily genetic.
Last December, a study in the journal PLOS One found that genetics usually explains no more than 5-10% of the risk for several common diseases. The study examined data from nearly 600 earlier studies identifying associations between common variations in the DNA sequence and more than 200 medical conditions. But its conclusion was stark: more than 95% of diseases or disease risks including Alzheimers, autism, asthma, juvenile diabetes, psoriasis, and so on could not be predicted accurately from the DNA sequence. A separate meta-analysis of two decades of DNA science corroborated this finding.
The implication is startling: that the entire premise for the billions of pounds this Government is investing in building a new privatised NHS infrastructure for AI-driven genomic medicine is scientifically unfounded.
The obsession with genetics can be traced directly back to the Prime Ministers chief advisor, Dominic Cummings.
Cummings set out his vision for the NHS in a February 2019 blog, which although previously reported on has not been fully appreciated for its astonishingly direct implications. While focusing on disease risk, the blog flagged-up Cummings hopes that a new NHS genomics prediction programme would ultimately allow the UK to, not just prevent diseases, but to do so before birth in effect a nod toward the selective breeding techniques at the core of eugenics.
They are using the COVID-19 crisis to erect a corporate superstate powered by mass surveillance and AI. Their grim ambition is to reach into the very DNA of every British citizen.
His vision for what a genomics-focused NHS would look like bears startling resemblance to the core ideas of eugenics the discredited pseudoscience aiming to improve the genetic quality of a human population by selecting for superior groups and excluding those with inferior genes. Its worst manifestations were exemplified by the Nazis.
In the blog, Cummings wrote:
Britain could contribute huge value to the world by leveraging existing assets, including scientific talent and how the NHS is structured, to push the frontiers of a rapidly evolving scientific field genomic prediction. He called for free universal SNP [single-nucleotide polymorphis] genetic sequencing as part of a shift to genuinely preventive medicine, to be rolled-out across the UK. This approach holds the promise of revolutionising healthcare in ways that give Britain some natural advantages over Europe and America.
Later in the post, Cummings allowed himself to speak more directly to what natural advantages could actually entail. He claimed that a combination of AI-driven machine learning with very large genetic sampling could enable the precise prediction of complex traits such as general intelligence and most diseases.
The two scientists Cummings cited as the primary sources for his vision were educational psychologist Robert Plomin and physicist Steven Hsu.
Plomin, described by Cummings as the worlds leading expert on the subject, is a renowned scientist. But he also has a history of association with the eugenics movement, according to Dr David King, founder of Human Genetics Alert and previously a molecular biologist. (Sir David King, the former chief scientific adviser to the UK Government, has also criticised the genome sequencing goldrush).*
When The Bell Curve a book advocating the genetic inferiority of African Americans was published, Plomin was a key signatory to a statement defending the science behind the book, explained Dr David King in a paper for the non-profit watchdog Human Genetics Alert. The statement carefully avoided explicitly endorsing The Bell Curves racist conclusions (aptly summarised by Francis Wheen as black people are more stupid than white people: always have been, always will be. This is why they have less economic and social success), while failing to repudiate them. Plomins fellow co-signatories included several self-proclaimed scientific racists, Philippe Rushton and Richard Lynn. Plomin has also published papers with the American Eugenics Society and spoken at several meetings of the British Eugenics Society (the latter rebranded itself as the Galton Institute in 1989) both of which advocated racial science.
In December 2013, Plomin was called as an expert witness to the House of Commons Education Select Committee, where he called for the Government to focus on the heritability of educational attainment. Twenty-five minutes into the session, Dominic Raab who as Foreign Secretary and First Secretary has stood in for Boris Johnson during his period of absence due to COVID-19 prompted Plomin to focus more specifically on explaining his views about genetics, intelligence and socio-economic status.
Just two months before Plomins parliamentary testimony, a 237-page dossier by Cummings then a top advisor to Education Secretary Michael Gove was leaked to the press. The paper claimed that genetics plays a bigger role in a childs IQ than teaching and called for giving specialist education as per Eton to the top 2% in IQ. Pete Shanks of the Centre for Genetics and Society described Cummings policy proposal as a blatantly eugenic association of genes with intelligence, intelligence with worth, and worth with the right to rule.
The Cummings dossier which cites Plomin extensively further reveals that, according to Cummings, he had invited Plomin into the DfE [Department for Education] to explain the science of IQ and genetics to officials and ministers.
The Education Select Committees report shows that, at the time of Plomins testimony, the Government was resistant to these views. But, the position appears to have changed since then, with figures such as Cummings, Raab and Gove now at the seat of power under Prime Minister Boris Johnson.
Plomin would go on to work with Steven Hsu, who was involved in a major Chinese genome sequencing project based on thousands of samples from very high-IQ people around the world. The goal was to identify genes that can predict intelligence. Hsu went on to launch his own company, Genomic Prediction. In slide presentations about his work from 2012, Hsu approvingly quoted British eugenicist Ronald Fisher, closing his slides with the following quotation: but such a race will inevitably arise in whatever country first sees the inheritance of mental characters elucidated. Hsus slides, wrote David King, include plans for a eugenic breeding scheme using embryo selection to improve the overall IQ of the population.
Yet, on his blog, Cummings confirmed that Hsu has recently attended a conference in the UK where he presented some of these ideas to UK policy-makers. Among the ideas Hsu presented to Cummings colleagues in Government was that the UK could become the world leader in genomic research by combining population-level genotyping with NHS health records. Hsu further claimed that risk prediction for common diseases was already available to guide early interventions that save lives and money.
Hopefully the NHS and Department for Health will play the Gretzky game, take expert advice from the likes of Plomin and Hsu and take this opportunity to make the UK a world leader in one of the most important frontiers in science, enthused Cummings.
Plomins claim that intelligence is determined primarily by genes contradicts a vast body of scientific literature, and is largely overblown. One of the latest studies debunking Cummings hopes was led by the University of Bristol and published in March. Based on a sample size of 3,500 children, the study found that polygenic scores (which combine information from all genetic material across the entire genome) have limited use for accurately predicting individual educational performance or for personalised education.
The study did not dismiss a role for genes outright, noting genetic scores modestly predictededucational achievement. The problem was that these predictions were less accurate than using standard information known to predicteducational outcomes, such as achievement at younger ages, parents educational attainment or family socio-economic position.
Last November, Hsus Genomic Prediction began touting new report cards to its customers. The cards displayed alleged results of genetic tests containing warnings that embryos might have low intelligence, grow up to be short, or have other conditions such as diabetes. But, according to the MIT Technology Review, the company has struggled both to validate its predictions and to interest fertility centres in them. In the month prior to Hsus grand announcement, the first major study to test the empirical viability of screening embryos, led by statistical geneticist Shai Carmi of the Hebrew University of Jerusalem, concluded that the technology is not plausible.
The lack of scientific substantiation has not stopped Cummings from suggesting a more interventionist vision for the NHS, which could be accused of paving the way for a new form of eugenics. In his February 2019 blog, he wrote: We can imagine everybody in the UK being given valuable information about their health for free,truly preventive medicinewhere we target resources at those most at risk, and early (evenin utero) identification of risks. This passage appears to nod to the core eugenics notion of selective breeding using embryo selection. Cummings even went further to endorse the goal of editing genes to fix problems.
In a further telling but slightly more well-known passage, Cummings characterised the genomics programme as a precursor to more realistic views about IQ and social mobility: It ought to go without saying that turning this idea into a political/government success requires focus on A) the NHS, health, science, NOT getting sidetracked into B) arguments about things like IQ and social mobility. Over time, the educated classes will continue to be dragged to more realistic views on (B) but this will be a complex process entangled with many hysterical episodes. (A) requires ruthless focus.
This passage affirms that Cummings approach is deliberately deceptive. The focus on health and the NHS is revealed as a cover for a longer-term vision to usher in more realistic views about things like IQ and social mobility. The passage also lifts the rock on Cummings weakest point that he fears that public attention on these more realistic views could sidetrack the broader strategy before it reaches fruition.
In the words of Dr David King, Cummings deference to Hsu, who openly advocated eugenics breeding programmes, suggests that the Prime Ministers chief advisor clearly favours this strategy for Britain; of course, this is precisely what all the European countries were trying to achieve in the heyday of eugenics to overcome their imperialist competitors by improving the national stock.
This, it seems, is the essence of Cummings ambition to use the NHS genomics prediction programme as a mechanism to provide Britain natural advantages over Europe and America.
And in this context, it is impossible to ignore the implications of Cummings appointment of Andrew Sabisky to a senior role advising Boris Johnson. When Johnsons spokespeople were asked repeatedly whether the Prime Minister would condemn Sabiskys sympathies for racist eugenics, he repeatedly refused. Sabisky later stepped away from the role.
The COVID-19 pandemic has now provided the Government with the opportunity to double down on its goals of extending genome sequencing across the UK population.
While genomic sequencing of the Coronavirus is undoubtedly an important scientific task to map and understand it, the crisis fits neatly into Cummings call for a ruthless focus on the NHS as a vehicle for Britains genetic enhancement.
On 23 March, when the UK finally instituted a lockdown at least three weeks after being informed that hundreds of thousands of people (and potentially up to a million) people were at risk of death from its previous policy of herd immunity, the Government launched a new scientific research consortium coordinated by Cambridge University along with the Wellcome Sanger Institute, the NHS and Public Health England.
The consortium would gather samples from patients confirmed with COVID-19 and send them to genetic sequencing centres across the country to analyse the whole genetic code of the samples. The project was billed breathlessly as an essential step in being able to control the pandemic and prevent further spread.
Unsurprisingly, it has done no such thing. Instead, six weeks later, the UK has ended up with the highest COVID-19 fatality rate in Europe.
As the death toll approaches the same level of British civilian casualties during the Second World War, the Governments strategy has privileged ambiguous, extortionate high technology solutions, pouring hundreds of millions of pounds into powerful private sector players with no transparency or due process. Meanwhile, traditional, proven, public health strategies such as better border controls, or extensive contact tracing and testing by scaling up local capacity, were inexplicably delayed for months.
On 13 March, the Government launched a new partnership between the NHS, Genomics England, the GenOMICC consortium, and US biotech giant Illumina, to conduct a nationwide human whole genome sequencing study targeting COVID-19 patients in 170 intensive care units.
The Governments new genome sequencing partner, Illumina, has previously produced genetic sequencing systems marketed to police agencies in China to facilitate its genetic profiling of the minority Uyghur population in Xinjang the largest system of discriminatory, ethnically-targeted biometric surveillance using DNA ever created.
It is difficult to avoid the conclusion that Dominic Cummings and his fellow ideologues in Government are hell-bent on pursuing a pseudo-scientific vision that has been years in the making.They are using the COVID-19 crisis to erect a corporate superstate powered by mass surveillance and AI. Their grim ambition is to reach into the very DNA of every British citizen.
Dominic Cummings was contacted for this article, but is yet to reply.
*This article was corrected to remove a confusion between Sir David King, the former government chief scientific adviser, and Dr David King, the molecular biologist who isthefounder and Director of Human Genetics Alert.
Read the original:
WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? - Byline Times
- Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer [Last Updated On: August 17th, 2024] [Originally Added On: May 3rd, 2010]
- A new mouse mutant of the Cdh23 gene with early-onset hearing loss facilitates evaluation of otoprotection drugs [Last Updated On: August 17th, 2024] [Originally Added On: August 2nd, 2010]
- Pharmacogenomics [Last Updated On: August 17th, 2024] [Originally Added On: October 10th, 2011]
- Drug Firms Want More Access to Genetic Specimens - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- India joins genome club -Genomics in India - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Classic: Weinshilboum: Inherited Variations in Drug and Neurotransmitter Metabolism 1981 - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict... - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 24th, 2011]
- Antidepressant Use Increases Significantly - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 28th, 2011]
- Kelan G. Tantisira, MD, MPH - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 31st, 2011]
- Human Security Thesis, personalized medicine, pharmacogenomics, Pharmacogenomics - Introduction - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pamela Sklar: 2011 Allen Institute for Brain Science Symposium - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pharmacy Doctor Oct 2011 A #1.wmv - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- R. Stephanie Huang, PhD: The Role of Pharmacogenomics and Anticancer Drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 19th, 2011]
- Individualized Molecular Testing for Personalized Medicine - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 21st, 2011]
- Where Science Meets Faith: Anticipating the Future - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 28th, 2011]
- Pharmacogenomics of psychotropic drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 6th, 2011]
- 2008 IPIT Awards Seminar: Hans Hogerzeil - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 7th, 2011]
- Asuragen CLIA Pharmacogenomic Services - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 8th, 2011]
- Pilot Demonstration Projects Group 4: Pharmacogenomics - Alan Shuldiner - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 16th, 2011]
- Pharmacogenomics - Howard McLeod - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 17th, 2011]
- Clinical Implementation of Psychiatric Pharmacogenomics - David Mrazek - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 10th, 2012]
- PROMISE - Bionexus Partnership Launching montage - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 16th, 2012]
- Dr. William Figg: Handling Pharmacogenomic Information - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 19th, 2012]
- Using Payer Data to Analyze Impact of Pharmacogenomic Approaches - Robert Epstein - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 22nd, 2012]
- Dr. Russ Altman on Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 26th, 2012]
- AssureRx Health Secures $8M Financing with Silicon Valley Bank to Support Growth [Last Updated On: August 17th, 2024] [Originally Added On: January 31st, 2012]
- BSc Biomedical Sciences courses at Brunel University - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 1st, 2012]
- Companion Diagnostics Market to Explode as Personalized Medicine Market Catapults to $42 Billion by 2015 [Last Updated On: August 17th, 2024] [Originally Added On: February 3rd, 2012]
- Gaming Wins Big at National Science Foundation's Visualization Challenge [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2012]
- SBCE to organise international meet on Molecular Medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- FDA Evaluating MolecularHealth's MASE for Analyzing Post-Market Drug Safety [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Genome BC Funds $9.8M Project to Identify Subgroups in Medulloblastoma for Personalized Treatment [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Future US Nucleic Acid Testing Market Outlook [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- China Clears Its First Microarray Platform for in Vitro Diagnostics to Accelerate Personalized Medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- ACLA Says Cuts in Medicare Lab Payments Could Hurt Nascent Personalized Dx Segment [Last Updated On: August 17th, 2024] [Originally Added On: February 20th, 2012]
- OncTerm- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 21st, 2012]
- A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer' [Last Updated On: August 17th, 2024] [Originally Added On: February 22nd, 2012]
- International meet on molecular medicine begins at SBCE [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Demonstrating Cost Effectiveness of Clinical NGS is Key to Payor Reimbursement, Hospital Uptake [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Darien High Schoolers fare well at science fair [Last Updated On: August 17th, 2024] [Originally Added On: February 27th, 2012]
- US Hematology & Flow Cytometry Market Future Discussed in New Report Published at MarketPublishers.com [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- ACM Global Central Lab Launches Workshop Series to Share Expert Insights on Navigating Global Clinical Trials with a ... [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Fitch: Drug Makers Continue to Face Challenges at the Beginning of the Drug Channel [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Will PCORI's Patient-Centered Comparative Effectiveness Research Track with Personalized Rx? [Last Updated On: August 17th, 2024] [Originally Added On: March 3rd, 2012]
- Generex to Meet with FDA about AE37 HER2 Peptide Vaccine; Companion Dx Path Still Unclear [Last Updated On: August 17th, 2024] [Originally Added On: March 6th, 2012]
- Vermillion's OVA1 Test Assigned Category 1 CPT Code; Stock Jumps [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic Reports Fiscal Year 2011 Financial Results [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic's Q4 Revenues Increase 69 Percent [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Research and Markets: Molecular Diagnostics: Market Segmentation and Opportunities - Emphasis on NGS and Its Emerging ... [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- AMA Approves Vermillion MAAA Category 1 Code for OVA1; Will it Improve Reimbursement? [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- USPSTF Updating BRCA Testing Recommendations for Asymptomatic Women; Accepting Public Input [Last Updated On: August 17th, 2024] [Originally Added On: March 8th, 2012]
- Global Biochips Market to Reach US$4.6 Billion by 2017, According to New Report by Global Industry Analysts, Inc. [Last Updated On: August 17th, 2024] [Originally Added On: March 10th, 2012]
- WSU venturing into pharmacogenomics - Tue, 13 Mar 2012 PST [Last Updated On: August 17th, 2024] [Originally Added On: March 13th, 2012]
- Research and Markets: Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice (6th ... [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- With MDx Usage and Costs on the Rise, UnitedHealthCare Urges Reimbursement Reform [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- WSU recruits geneticists in new research venture [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Free Book Download - Psychiatric Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 16th, 2012]
- PanGenX Takes Semantic-based Approach to Data Integration, Analytics for Personalized Medicine [Last Updated On: August 17th, 2024] [Originally Added On: March 17th, 2012]
- Research and Markets: Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- Quest Launches MDx that May Predict Kidney Transplant Rejection Earlier than Current Methods [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- EMERGE Network Launches Publicly Available Database of Phenotype Identification Algorithms [Last Updated On: August 17th, 2024] [Originally Added On: March 23rd, 2012]
- Prospective Outcomes Trial Shows Agendia's MammaPrint Safely Reduces Chemo Use in Low-Risk Patients [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Abbott Challenges 'Incorrect Assumptions' in Cost-Effectiveness Study of Xalkori PGx Testing [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Genoptix Says NGS Melanoma Test Will Not Be Used to Place Patients in Trials for Parent Novartis [Last Updated On: August 17th, 2024] [Originally Added On: March 28th, 2012]
- St. Jude's Evans Receives Pharmacists Assn. Award [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Perkins Chain Hires New CEO [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- PGx Highlights from American College of Cardiology Annual Meeting [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Collecting Cancer Data [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- UNC Analysis Finds Beta1-AR Alleles Impact Survival in Patients Treated with Beta-Blockers [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Q&A: GE Healthcare's Mark Dente on the Challenges of Integrating Genomics Data with EMRs [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- Eastday-Neurosurgeon, geneticist take top prizes in science [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- A New 'Omics Emerges [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- Up to the Task [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- NHGRI Plans to Fund More Clinical Sequencing Projects [Last Updated On: August 17th, 2024] [Originally Added On: April 7th, 2012]
- Doctor’s role is key to cancer fight [Last Updated On: August 17th, 2024] [Originally Added On: April 16th, 2012]
- People in the News: Josh LaBaer in as New President of US HUPO and More [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]
- Convey, CLC Bio to Provide Combined Software, Hardware NGS Data-Analysis Solution [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]